Provided by Tiger Trade Technology Pte. Ltd.

MoonLake Immunotherapeutics

17.32
-0.4300-2.42%
Post-market: 17.20-0.1200-0.69%19:58 EDT
Volume:478.92K
Turnover:8.34M
Market Cap:1.24B
PE:-4.91
High:17.89
Open:17.68
Low:17.19
Close:17.75
52wk High:62.75
52wk Low:5.95
Shares:71.37M
Float Shares:40.42M
Volume Ratio:0.59
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5300
EPS(LYR):-3.5300
ROE:-60.78%
ROA:-33.92%
PB:4.06
PE(LYR):-4.91

Loading ...

Company Profile

Company Name:
MoonLake Immunotherapeutics
Exchange:
NASDAQ
Establishment Date:
2021
Employees:
130
Office Location:
Dorfstrasse 29,Zug,Zug,Switzerland
Zip Code:
6300
Fax:
- -
Introduction:
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis. MoonLake Immunotherapeutics was incorporated in 2021 and is headquartered in Zug, Switzerland.

Directors

Name
Position
Jorge Santos da Silva
Chief Executive Officer,Director and Interim Chair of the Board
Andrew J. Phillips
Independent Director
Catherine Moukheibir
Independent Director
Ramnik Xavier
Independent Director
Spike Loy
Lead Independent Director

Shareholders

Name
Position
Jorge Santos da Silva
Chief Executive Officer,Director and Interim Chair of the Board
Matthias Bodenstedt
Chief Financial Officer
Kristian Reich
Chief Scientific Officer